{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T20:39:28Z","timestamp":1792528768710,"version":"4.5.0"},"reference-count":158,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"The Construction Fund of Key Medical Disciplines of Hangzhou","award":["2025HZZD02"],"award-info":[{"award-number":["2025HZZD02"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82470182"],"award-info":[{"award-number":["82470182"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11864-026-01402-3","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T06:30:07Z","timestamp":1783578607000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiotoxicity of Targeted Therapies in Hematologic Malignancies: From Molecular Mechanisms to Clinical Management"],"prefix":"10.1007","volume":"27","author":[{"given":"Mengmeng","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nengming","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangmin","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4461-478X","authenticated-orcid":false,"given":"Yangling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"issue":"1","key":"1402_CR1","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41408-023-00853-3","volume":"13","author":"N Zhang","year":"2023","unstructured":"Zhang N, Wu J, Wang Q, Liang Y, Li X, Chen G, Zhou F, et al. Global burden of hematologic malignancies and evolution patterns over the past 30 years. Blood Cancer J. 2023;13(1):82.","journal-title":"Blood Cancer J"},{"issue":"5","key":"1402_CR2","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41408-020-0323-4","volume":"10","author":"D Pulte","year":"2020","unstructured":"Pulte D, Jansen L, Brenner H. Changes in long term survival after diagnosis with common hematologic malignancies in the early 21st century. Blood Cancer J. 2020;10(5):56.","journal-title":"Blood Cancer J"},{"issue":"1","key":"1402_CR3","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/s41392-020-00361-x","volume":"5","author":"JL Carter","year":"2020","unstructured":"Carter JL, Hege K, Yang J, Kalpage HA, Su Y, Edwards H, Ge Y, et al. Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy. Signal Transduct Target Ther. 2020;5(1):288.","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"1402_CR4","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/joim.13697","volume":"294","author":"R Rosenquist","year":"2023","unstructured":"Rosenquist R, Bernard E, Erkers T, Scott DW, Itzykson R, Rousselot P, Smedby KE, et al. Novel precision medicine approaches and treatment strategies in hematological malignancies. J Intern Med. 2023;294(4):413\u201336.","journal-title":"J Intern Med"},{"issue":"8","key":"1402_CR5","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41569-020-0348-1","volume":"17","author":"J Herrmann","year":"2020","unstructured":"Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat Rev Cardiol. 2020;17(8):474\u2013502.","journal-title":"Nat Rev Cardiol"},{"issue":"4","key":"1402_CR6","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","volume":"43","author":"J Herrmann","year":"2022","unstructured":"Herrmann J, Lenihan D, Armenian S, Barac A, Blaes A, Cardinale D, Valent P, et al. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J. 2022;43(4):280\u201399.","journal-title":"Eur Heart J"},{"issue":"8","key":"1402_CR7","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41569-020-0348-1","volume":"17","author":"J Herrmann","year":"2020","unstructured":"Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat Reviews Cardiol. 2020;17(8):474\u2013502.","journal-title":"Nat Reviews Cardiol"},{"issue":"1","key":"1402_CR8","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41392-021-00641-0","volume":"6","author":"F Wu","year":"2021","unstructured":"Wu F, Yang J, Liu J, Wang Y, Mu J, Zeng Q, Zhou H, et al. Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer. Signal Transduct Target Ther. 2021;6(1):218.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"1402_CR9","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","volume":"6","author":"L Zhong","year":"2021","unstructured":"Zhong L, Li Y, Xiong L, Wang W, Wu M, Yuan T, Yang S, et al. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduct Target Ther. 2021;6(1):201.","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"1402_CR10","first-page":"e23855","volume":"14","author":"G Arora","year":"2022","unstructured":"Arora G, Adinugraha P, Aijaz A, Vargas Pelaez A, Rachko M. Pericardial Effusion Secondary to Nilotinib in an Elderly Patient With Chronic Myelogenous Leukemia. Cureus. 2022;14(4):e23855.","journal-title":"Cureus"},{"issue":"1","key":"1402_CR11","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1158\/1078-0432.CCR-20-1600","volume":"27","author":"L Zhang","year":"2021","unstructured":"Zhang L, Meng L, Liu B, Zhang Y, Zhu H, Cui J, Wang J, et al. Flumatinib versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Phase III, Randomized, Open-label, Multi-center FESTnd Study. Clin Cancer Res. 2021;27(1):70\u20137.","journal-title":"Clin Cancer Res"},{"key":"1402_CR12","first-page":"1816287","volume":"2019","author":"T Takakuwa","year":"2019","unstructured":"Takakuwa T, Otomaru I, Araki T, Miura A, Fujitani Y, Mochizuki Y, Yamamura R, et al. The First Autopsy Case of Fatal Acute Cardiac Failure after Administration of Carfilzomib in a Patient with Multiple Myeloma. Case Rep Hematol. 2019;2019:1816287.","journal-title":"Case Rep Hematol"},{"issue":"4","key":"1402_CR13","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1159\/000340050","volume":"128","author":"M Bockorny","year":"2012","unstructured":"Bockorny M, Chakravarty S, Schulman P, Bockorny B, Bona R. Severe heart failure after bortezomib treatment in a patient with multiple myeloma: a case report and review of the literature. Acta Haematol. 2012;128(4):244\u20137.","journal-title":"Acta Haematol"},{"issue":"3","key":"1402_CR14","doi-asserted-by":"publisher","first-page":"ytac093","DOI":"10.1093\/ehjcr\/ytac093","volume":"6","author":"M Verbesselt","year":"2022","unstructured":"Verbesselt M, Meekers E, Vandenberghe P, Delforge M, Vandenbriele C. Combined lenalidomide\/bortezomib for multiple myeloma complicated by fulminant myocarditis: a rare case report of widely used chemotherapy. Eur Heart J Case Rep. 2022;6(3):ytac093.","journal-title":"Eur Heart J Case Rep"},{"issue":"3","key":"1402_CR15","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1159\/000520382","volume":"14","author":"Y Alali","year":"2021","unstructured":"Alali Y, Baljevic M. Bortezomib-Induced Perimyocarditis in a Multiple Myeloma Patient: A Case Report. Case Rep Oncol. 2021;14(3):1853\u20139.","journal-title":"Case Rep Oncol"},{"issue":"18","key":"1402_CR16","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1182\/blood.2020006844","volume":"136","author":"CS Tam","year":"2020","unstructured":"Tam CS, Opat S, D\u2019Sa S, Jurczak W, Lee H-P, Cull G, et al. Dimopoulos M. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: the ASPEN study. Blood. 2020;136(18):2038\u201350.","journal-title":"Blood"},{"issue":"4","key":"1402_CR17","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa2211582","volume":"388","author":"JR Brown","year":"2023","unstructured":"Brown JR, Eichhorst B, Hillmen P, Jurczak W, Ka\u017amierczak M, Lamanna N, et al. Shadman M. Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. N Engl J Med. 2023;388(4):319\u201332.","journal-title":"N Engl J Med"},{"issue":"2","key":"1402_CR18","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/ajh.24608","volume":"92","author":"H Jouni","year":"2017","unstructured":"Jouni H, Aubry MC, Lacy MQ, Vincent Rajkumar S, Kumar SK, Frye RL, Herrmann J. Ixazomib cardiotoxicity: A possible class effect of proteasome inhibitors. Am J Hematol. 2017;92(2):220\u20131.","journal-title":"Am J Hematol"},{"issue":"4","key":"1402_CR19","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/phar.1733","volume":"36","author":"M Newman","year":"2016","unstructured":"Newman M, Malla M, Gojo I. Azacitidine-Induced Pericarditis: A Case Series. Pharmacotherapy. 2016;36(4):443\u20138.","journal-title":"Pharmacotherapy"},{"issue":"6","key":"1402_CR20","first-page":"849","volume":"35","author":"M Ismayl","year":"2022","unstructured":"Ismayl M, Kc A, Thandra A, Sricharoen N, Arouni A. Azacitidine-induced myopericarditis in acute myeloid leukemia. Proc (Bayl Univ Med Cent). 2022;35(6):849\u201351.","journal-title":"Proc (Bayl Univ Med Cent)"},{"issue":"4","key":"1402_CR21","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1177\/10781552211073884","volume":"28","author":"M Foga\u00e7a da Mata","year":"2022","unstructured":"Foga\u00e7a da Mata M, Vieira Martins M, Rato J, Madeira M, Gon\u00e7alves J-P, Teixeira A, Anjos R. Azacitidine-induced massive pericardial effusion in a child with myelodysplastic syndrome. J Oncol Pharm Pract. 2022;28(4):975\u20138.","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"1402_CR22","first-page":"4","volume":"9","author":"A Sheel","year":"2023","unstructured":"Sheel A, Bae J, Asada A, Otterson GA, Baliga RR, Koenig KL. Reversible cardiomyopathy in a patient with chronic myelomonocytic leukemia treated with decitabine\/cedazuridine: a case report. Cardiooncology. 2023;9(1):4.","journal-title":"Cardiooncology"},{"issue":"4","key":"1402_CR23","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1111\/bjh.19325","volume":"204","author":"IM Johnson","year":"2024","unstructured":"Johnson IM, Karrar O, Rana M, Iftikhar M, Chen S, McCullough K, et al. Gangat N. Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax\u2009+\u2009hypomethylating agents. Br J Haematol. 2024;204(4):1232\u20137.","journal-title":"Br J Haematol"},{"issue":"2","key":"1402_CR24","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/hon.2828","volume":"39","author":"I Amitai","year":"2021","unstructured":"Amitai I, Gafter-Gvili A, Shargian-Alon L, Raanani P, Gurion R. Obinutuzumab-related adverse events: A systematic review and meta-analysis. Hematol Oncol. 2021;39(2):215\u201321.","journal-title":"Hematol Oncol"},{"issue":"5","key":"1402_CR25","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1080\/14740338.2024.2327507","volume":"23","author":"S Xiang","year":"2024","unstructured":"Xiang S, Shen R, Xiang J, Zhu N, Gu J, Shen J, Ge H, et al. A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for Bruton\u2019s tyrosine kinase inhibitors (BTKis) single and its combination therapy. Expert Opin Drug Saf. 2024;23(5):627\u201336.","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"1402_CR26","doi-asserted-by":"publisher","first-page":"e288","DOI":"10.1177\/030089161309900622","volume":"99","author":"C Passalia","year":"2013","unstructured":"Passalia C, Minetto P, Arboscello E, Balleari E, Bellodi A, Del Corso L, et al. Ghio R. Cardiovascular adverse events complicating the administration of rituximab: report of two cases. Tumori. 2013;99(6):e288\u201392.","journal-title":"Tumori"},{"issue":"1","key":"1402_CR27","doi-asserted-by":"publisher","first-page":"18","DOI":"10.15171\/jrip.2017.04","volume":"6","author":"W Cheungpasitporn","year":"2017","unstructured":"Cheungpasitporn W, Kopecky SL, Specks U, Bharucha K, Fervenza FC. Non-ischemic cardiomyopathy after rituximab treatment for membranous nephropathy. J Ren Inj Prev. 2017;6(1):18\u201325.","journal-title":"J Ren Inj Prev"},{"issue":"4","key":"1402_CR28","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3816\/CLM.2008.n.035","volume":"8","author":"JD Armitage","year":"2008","unstructured":"Armitage JD, Montero C, Benner A, Armitage JO, Bociek G. Acute coronary syndromes complicating the first infusion of rituximab. Clin Lymphoma Myeloma. 2008;8(4):253\u20135.","journal-title":"Clin Lymphoma Myeloma"},{"issue":"2","key":"1402_CR29","first-page":"187","volume":"15","author":"AN Keswani","year":"2015","unstructured":"Keswani AN, Williams C, Fuloria J, Polin NM, Jahangir E. Rituximab-Induced Acute ST Elevation Myocardial Infarction. Ochsner J. 2015;15(2):187\u201390.","journal-title":"Ochsner J"},{"issue":"16","key":"1402_CR30","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.2169\/internalmedicine.2596-18","volume":"58","author":"K Matsuo","year":"2019","unstructured":"Matsuo K, Ishiguro T, Najama T, Shimizu Y, Kobayashi Y, Mutou M. Nivolumab-induced Myocarditis Successfully Treated with Corticosteroid Therapy: A Case Report and Review of the Literature. Intern Med. 2019;58(16):2367\u201372.","journal-title":"Intern Med"},{"issue":"3","key":"1402_CR31","first-page":"e80732","volume":"17","author":"S Fukushima","year":"2025","unstructured":"Fukushima S, Okamoto E, Uchida T, Kijima T. A Case of Nivolumab-Induced Multiorgan Toxicity: Concurrent Myocarditis and Interstitial Pneumonia. Cureus. 2025;17(3):e80732.","journal-title":"Cureus"},{"issue":"1","key":"1402_CR32","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s40425-018-0473-0","volume":"6","author":"C Monge","year":"2018","unstructured":"Monge C, Maeng H, Brofferio A, Apolo AB, Sathya B, Arai AE, et al. Bilusic M. Myocarditis in a patient treated with Nivolumab and PROSTVAC: a case report. J Immunother Cancer. 2018;6(1):150.","journal-title":"J Immunother Cancer"},{"issue":"5","key":"1402_CR33","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.jaccao.2023.09.002","volume":"5","author":"C Quartermaine","year":"2023","unstructured":"Quartermaine C, Ghazi SM, Yasin A, Awan FT, Fradley M, Wiczer T, et al. Addison D. Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol. 2023;5(5):570\u201390.","journal-title":"JACC CardioOncol"},{"issue":"31","key":"1402_CR34","doi-asserted-by":"publisher","first-page":"3453","DOI":"10.1200\/JCO.21.00693","volume":"39","author":"H Abdel-Qadir","year":"2021","unstructured":"Abdel-Qadir H, Sabrie N, Leong D, Pang A, Austin PC, Prica A, et al. Thavendiranathan P. Cardiovascular Risk Associated With Ibrutinib Use in Chronic Lymphocytic Leukemia: A Population-Based Cohort Study. J Clin Oncol. 2021;39(31):3453\u201362.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1402_CR35","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s11886-023-01916-4","volume":"25","author":"N Aghel","year":"2023","unstructured":"Aghel N, Baro Vila RC, Lui M, Hillis C, Leong DP. Diagnosis and management of cardiovascular effects of Bruton\u2019s tyrosine kinase inhibitors. Curr Cardiol Rep. 2023;25(9):941\u201358.","journal-title":"Curr Cardiol Rep"},{"issue":"31","key":"1402_CR36","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1200\/JCO.21.01210","volume":"39","author":"JC Byrd","year":"2021","unstructured":"Byrd JC, Hillmen P, Ghia P, Kater AP, Chanan-Khan A, Furman RR, et al. Jurczak W. Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. J Clin Oncol. 2021;39(31):3441\u201352.","journal-title":"J Clin Oncol"},{"key":"1402_CR37","doi-asserted-by":"publisher","unstructured":"Yang Y, Liu Y, Sun H, Meng L, Lin H, Chen C, et al. Safety and efficacy of flumatinib as later-line therapy in patients with chronic myeloid leukemia. Haematologica. 2024. 109(12):3965\u20133974. https:\/\/doi.org\/10.3324\/haematol.2023.284892","DOI":"10.3324\/haematol.2023.284892"},{"issue":"6","key":"1402_CR38","doi-asserted-by":"publisher","first-page":"e257","DOI":"10.1016\/j.clml.2024.02.008","volume":"24","author":"X Zhang","year":"2024","unstructured":"Zhang X, Xu N, Yang Y, Lin H, Liu B, Du X, Jiang Q, et al. Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective Study. Clin Lymphoma Myeloma Leuk. 2024;24(6):e257\u201366.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"1402_CR39","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1182\/blood.2022018818","volume":"142","author":"JF Seymour","year":"2023","unstructured":"Seymour JF, Byrd JC, Ghia P, Kater AP, Chanan-Khan A, Furman RR, Woyach JA, et al. Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial. Blood. 2023;142(8):687\u201399.","journal-title":"Blood"},{"issue":"10","key":"1402_CR40","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1182\/bloodadvances.2023011641","volume":"8","author":"JJ Moslehi","year":"2024","unstructured":"Moslehi JJ, Furman RR, Tam CS, Salem JE, Flowers CR, Cohen A, et al. Cardiovascular events reported in patients with B-cell malignancies treated with zanubrutinib. Blood Adv. 2024;8(10):2478\u201390.","journal-title":"Blood Adv"},{"issue":"9","key":"1402_CR41","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1111\/bcp.16127","volume":"90","author":"Z-X Zhao","year":"2024","unstructured":"Zhao Z-X, Yang T-Y, Wang Y-H, Zhang L, Li J, Su Y-W. Cardiovascular events of Bruton\u2019s tyrosine kinase inhibitors: A real-world study based on the United States Food and Drug Administration Adverse Event Reporting System database. Br J Clin Pharmacol. 2024;90(9):2166\u201379.","journal-title":"Br J Clin Pharmacol"},{"key":"1402_CR42","doi-asserted-by":"publisher","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994\u20131004. https:\/\/doi.org\/10.1056\/NEJMoa022457","DOI":"10.1056\/NEJMoa022457"},{"issue":"10","key":"1402_CR43","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Druker BJ. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N Engl J Med. 2017;376(10):917\u201327.","journal-title":"N Engl J Med"},{"issue":"5","key":"1402_CR44","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","volume":"119","author":"HM Kantarjian","year":"2012","unstructured":"Kantarjian HM, Shah NP, Cortes JE, Baccarani M, Agarwal MB, Undurraga MS, Hochhaus A, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012;119(5):1123\u20139.","journal-title":"Blood"},{"issue":"1","key":"1402_CR45","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1182\/asheducation-2017.1.110","volume":"2017","author":"MC Barber","year":"2017","unstructured":"Barber MC, Mauro MJ, Moslehi J. Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy. Hematol Am Soc Hematol Educ Program. 2017;2017(1):110\u20134.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"1402_CR46","doi-asserted-by":"publisher","first-page":"675811","DOI":"10.3389\/fphys.2021.675811","volume":"12","author":"M Santoro","year":"2021","unstructured":"Santoro M, Mancuso S, Accurso V, Di Lisi D, Novo G, Siragusa S. Cardiovascular Issues in Tyrosine Kinase Inhibitors Treatments for Chronic Myeloid Leukemia: A Review. Front Physiol. 2021;12:675811.","journal-title":"Front Physiol"},{"key":"1402_CR47","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ijcard.2020.05.077","volume":"316","author":"AP Singh","year":"2020","unstructured":"Singh AP, Umbarkar P, Tousif S, Lal H. Cardiotoxicity of the BCR-ABL1 tyrosine kinase inhibitors: Emphasis on ponatinib. Int J Cardiol. 2020;316:214\u201321.","journal-title":"Int J Cardiol"},{"issue":"5","key":"1402_CR48","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1161\/CIRCRESAHA.123.323683","volume":"134","author":"G Yan","year":"2024","unstructured":"Yan G, Han Z, Kwon Y, Jousma J, Nukala SB, Prosser BL, et al. Ong S-G. Integrated Stress Response Potentiates Ponatinib-Induced Cardiotoxicity. Circ Res. 2024;134(5):482\u2013501.","journal-title":"Circ Res"},{"issue":"10388","key":"1402_CR49","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","volume":"401","author":"HP Erba","year":"2023","unstructured":"Erba HP, Montesinos P, Kim H-J, Patkowska E, Vrhovac R, \u017d\u00e1k P, Schlenk RF, et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401(10388):1571\u201383.","journal-title":"Lancet"},{"issue":"5","key":"1402_CR50","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1056\/NEJMoa1409002","volume":"372","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, Verstovsek S, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372(5):426\u201335.","journal-title":"N Engl J Med"},{"issue":"10","key":"1402_CR51","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.3324\/haematol.2017.164103","volume":"102","author":"I de Weerdt","year":"2017","unstructured":"de Weerdt I, Koopmans SM, Kater AP, van Gelder M. Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach. Haematologica. 2017;102(10):1629\u201339.","journal-title":"Haematologica"},{"key":"1402_CR52","doi-asserted-by":"publisher","first-page":"1034253","DOI":"10.3389\/fimmu.2022.1034253","volume":"13","author":"J Wang","year":"2022","unstructured":"Wang J, Zhou H, Mu M, Zhao A, Cai Z, Li L, Niu T, et al. Efficacy and safety of copanlisib in relapsed\/refractory B-cell non-Hodgkin lymphoma: A meta-analysis of prospective clinical trials. Front Immunol. 2022;13:1034253.","journal-title":"Front Immunol"},{"issue":"6467","key":"1402_CR53","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1126\/science.aax3769","volume":"366","author":"C Pohl","year":"2019","unstructured":"Pohl C, Dikic I. Cellular quality control by the ubiquitin-proteasome system and autophagy. Science. 2019;366(6467):818\u201322.","journal-title":"Science"},{"issue":"11","key":"1402_CR54","doi-asserted-by":"publisher","first-page":"e13715","DOI":"10.1111\/acel.13715","volume":"21","author":"E-D Papanagnou","year":"2022","unstructured":"Papanagnou E-D, Gumeni S, Sklirou AD, Rafeletou A, Terpos E, Keklikoglou K, et al. Trougakos IP. Autophagy activation can partially rescue proteasome dysfunction-mediated cardiac toxicity. Aging Cell. 2022;21(11):e13715.","journal-title":"Aging Cell"},{"issue":"7","key":"1402_CR55","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nrclinonc.2016.206","volume":"14","author":"EE Manasanch","year":"2017","unstructured":"Manasanch EE, Orlowski RZ. Proteasome inhibitors in cancer therapy. Nat Rev Clin Oncol. 2017;14(7):417\u201333.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"1402_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaccao.2022.12.005","volume":"5","author":"G Georgiopoulos","year":"2023","unstructured":"Georgiopoulos G, Makris N, Laina A, Theodorakakou F, Briasoulis A, Trougakos IP, Stamatelopoulos K, et al. Cardiovascular Toxicity of Proteasome Inhibitors: Underlying Mechanisms and Management Strategies: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol. 2023;5(1):1\u201321.","journal-title":"JACC CardioOncol"},{"issue":"1","key":"1402_CR57","doi-asserted-by":"publisher","first-page":"30","DOI":"10.2174\/1871529X21666210412113017","volume":"21","author":"A Latif","year":"2021","unstructured":"Latif A, Kapoor V, Lateef N, Ahsan MJ, Usman RM, Malik SU, Anwer F, et al. Incidence and Management of Carfilzomib-induced Cardiovascular Toxicity; A Systematic Review and Meta-analysis. Cardiovasc Hematol Disord Drug Targets. 2021;21(1):30\u201345.","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"issue":"1","key":"1402_CR58","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/cam4.3568","volume":"10","author":"R Bishnoi","year":"2021","unstructured":"Bishnoi R, Xie Z, Shah C, Bian J, Murthy HS, Wingard JR, Farhadfar N. Real-world experience of carfilzomib-associated cardiovascular adverse events: SEER-Medicare data set analysis. Cancer Med. 2021;10(1):70\u20138.","journal-title":"Cancer Med"},{"issue":"12","key":"1402_CR59","first-page":"e20295","volume":"13","author":"SH Sundaravel","year":"2021","unstructured":"Sundaravel SH, Marar RI, Abbasi MA, Baljevic M, Stone JR. Bortezomib-Induced Reversible Cardiomyopathy: Recovered With Guideline-Directed Medical Therapy. Cureus. 2021;13(12):e20295.","journal-title":"Cureus"},{"issue":"8","key":"1402_CR60","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1007\/s00277-024-05691-2","volume":"103","author":"W Li","year":"2024","unstructured":"Li W, Fu Y, Wang W. A real-world pharmacovigilance study investigating the toxicities of histone deacetylase inhibitors. Ann Hematol. 2024;103(8):3207\u201317.","journal-title":"Ann Hematol"},{"issue":"5","key":"1402_CR61","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.hlc.2024.01.013","volume":"33","author":"L Balachandran","year":"2024","unstructured":"Balachandran L, Haw TJ, Leong AJW, Croft AJ, Chen D, Kelly C, et al. Ngo DTM. Cancer Therapies and Cardiomyocyte Viability: Which Drugs are Directly Cardiotoxic? Heart Lung Circ. 2024;33(5):747\u201352.","journal-title":"Heart Lung Circ"},{"issue":"1","key":"1402_CR62","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/S1470-2045(20)30680-X","volume":"22","author":"JP Laubach","year":"2021","unstructured":"Laubach JP, Schjesvold F, Mariz M, Dimopoulos MA, Lech-Maranda E, Spicka I, Richardson PG, et al. Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study. Lancet Oncol. 2021;22(1):142\u201354.","journal-title":"Lancet Oncol"},{"issue":"4","key":"1402_CR63","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1002\/ajh.26088","volume":"96","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Gregory TK, Faber EA, Hart LL, Mace JR, Arrowsmith ER, Matous JV, et al. A phase I\/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed\/refractory multiple myeloma: Final analysis of second dose-expansion cohort. Am J Hematol. 2021;96(4):428\u201335.","journal-title":"Am J Hematol"},{"issue":"10","key":"1402_CR64","doi-asserted-by":"publisher","first-page":"8337","DOI":"10.3390\/cimb45100526","volume":"45","author":"Y Samuel","year":"2023","unstructured":"Samuel Y, Babu A, Karagkouni F, Ismail A, Choi S, Boussios S. Cardiac Toxicities in Oncology: Elucidating the Dark Box in the Era of Precision Medicine. Curr Issues Mol Biol. 2023;45(10):8337\u201358.","journal-title":"Curr Issues Mol Biol"},{"issue":"9","key":"1402_CR65","doi-asserted-by":"publisher","first-page":"e406","DOI":"10.1016\/S1470-2045(22)00221-2","volume":"23","author":"EL Giraud","year":"2022","unstructured":"Giraud EL, Ferrier KRM, Lankheet NAG, Desar IME, Steeghs N, Beukema RJ, Smolders EJ, et al. The QT interval prolongation potential of anticancer and supportive drugs: a comprehensive overview. Lancet Oncol. 2022;23(9):e406\u201315.","journal-title":"Lancet Oncol"},{"key":"1402_CR66","doi-asserted-by":"publisher","first-page":"325","DOI":"10.4137\/CMO.S8598","volume":"6","author":"C De","year":"2012","unstructured":"De C, Phookan J, Parikh V, Nagrani T, Lakhani M, Forte F, Lafferty J. Decitabine induced transient cardiomyopathy: a case report. Clin Med Insights Oncol. 2012;6:325\u20139.","journal-title":"Clin Med Insights Oncol"},{"issue":"2","key":"1402_CR67","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1159\/000526610","volume":"68","author":"B Chu","year":"2023","unstructured":"Chu B, Venkatakrishnan A, Aggarwal P. Safety Signal between Azacitidine and Pericarditis. Chemotherapy. 2023;68(2):115\u20138.","journal-title":"Chemotherapy"},{"key":"1402_CR68","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2147\/CE.S172912","volume":"14","author":"M Galkin","year":"2019","unstructured":"Galkin M, Jonas BA. Enasidenib in the treatment of relapsed\/refractory acute myeloid leukemia: an evidence-based review of its place in therapy. Core Evid. 2019;14:3\u201317.","journal-title":"Core Evid"},{"issue":"12","key":"1402_CR69","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1182\/blood-2018-02-791350","volume":"132","author":"R Valentin","year":"2018","unstructured":"Valentin R, Grabow S, Davids MS. The rise of apoptosis: targeting apoptosis in hematologic malignancies. Blood. 2018;132(12):1248\u201364.","journal-title":"Blood"},{"issue":"12","key":"1402_CR70","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","volume":"378","author":"JF Seymour","year":"2018","unstructured":"Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D\u2019Rozario J, Assouline S, Kater AP, et al. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. N Engl J Med. 2018;378(12):1107\u201320.","journal-title":"N Engl J Med"},{"issue":"17","key":"1402_CR71","doi-asserted-by":"publisher","first-page":"5227","DOI":"10.1182\/bloodadvances.2022007333","volume":"6","author":"IM Johnson","year":"2022","unstructured":"Johnson IM, Bezerra ED, Farrukh F, McCullough K, Al-Kali A, Alkhateeb HB, et al. Gangat N. Cardiac events in patients with acute myeloid leukemia treated with venetoclax combined with hypomethylating agents. Blood Adv. 2022;6(17):5227\u201331.","journal-title":"Blood Adv"},{"issue":"5","key":"1402_CR72","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1586\/eci.09.31","volume":"5","author":"PJ Bugelski","year":"2009","unstructured":"Bugelski PJ, Achuthanandam R, Capocasale RJ, Treacy G, Bouman-Thio E. Monoclonal antibody-induced cytokine-release syndrome. Expert Rev Clin Immunol. 2009;5(5):499\u2013521.","journal-title":"Expert Rev Clin Immunol"},{"issue":"5","key":"1402_CR73","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s00228-025-03824-8","volume":"81","author":"MA Barbieri","year":"2025","unstructured":"Barbieri MA, Russo G, Cicala G, And\u00f2 G, Franchina T, Silvestris N, Spina E, et al. Unveiling cardiovascular and respiratory toxicities with monoclonal antibodies in multiple myeloma: disproportionality analysis from the FDA Adverse Event Reporting System. Eur J Clin Pharmacol. 2025;81(5):755\u201370.","journal-title":"Eur J Clin Pharmacol"},{"issue":"11","key":"1402_CR74","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1161\/CIRCRESAHA.120.315894","volume":"128","author":"AH Baik","year":"2021","unstructured":"Baik AH, Oluwole OO, Johnson DB, Shah N, Salem J-E, Tsai KK, Moslehi JJ. Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies. Circ Res. 2021;128(11):1780\u2013801.","journal-title":"Circ Res"},{"key":"1402_CR75","doi-asserted-by":"publisher","unstructured":"Sayed A, Munir M, Ghazi SM, Ferdousi M, Krishan S, Shaaban A, et al. Cardiovascular toxicities associated with bispecific T-cell engager therapy. J Immunother Cancer. 2024 Feb 21;12(2):e008518. https:\/\/doi.org\/10.1136\/jitc-2023-008518","DOI":"10.1136\/jitc-2023-008518"},{"issue":"6","key":"1402_CR76","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","volume":"22","author":"PF Caimi","year":"2021","unstructured":"Caimi PF, Ai W, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, et al. Carlo-Stella C. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2021;22(6):790\u2013800.","journal-title":"Lancet Oncol"},{"key":"1402_CR77","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.tox.2017.03.006","volume":"382","author":"TP Chambers","year":"2017","unstructured":"Chambers TP, Santiesteban L, Gomez D, Chambers JW. Sab mediates mitochondrial dysfunction involved in imatinib mesylate-induced cardiotoxicity. Toxicology. 2017;382:24\u201335.","journal-title":"Toxicology"},{"key":"1402_CR78","doi-asserted-by":"publisher","first-page":"108866","DOI":"10.1016\/j.abb.2021.108866","volume":"704","author":"HH Mansour","year":"2021","unstructured":"Mansour HH, El Kiki SM, Ibrahim AB, Omran MM. Effect of l-carnitine on cardiotoxicity and apoptosis induced by imatinib through PDGF\/ PPAR\u03b3 \/MAPK pathways. Arch Biochem Biophys. 2021;704:108866.","journal-title":"Arch Biochem Biophys"},{"key":"1402_CR79","doi-asserted-by":"publisher","first-page":"115852","DOI":"10.1016\/j.taap.2021.115852","volume":"435","author":"C Song","year":"2022","unstructured":"Song C, Li D, Zhang J, Zhao X. Role of ferroptosis in promoting cardiotoxicity induced by Imatinib Mesylate via down-regulating Nrf2 pathways in vitro and in vivo. Toxicol Appl Pharmacol. 2022;435:115852.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"2","key":"1402_CR80","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1039\/D2FO03331C","volume":"14","author":"C Song","year":"2023","unstructured":"Song C, Li D, Zhang J, Zhao X. Berberine hydrochloride alleviates imatinib mesylate - induced cardiotoxicity through the inhibition of Nrf2-dependent ferroptosis. Food Funct. 2023;14(2):1087\u201398.","journal-title":"Food Funct"},{"key":"1402_CR81","doi-asserted-by":"publisher","first-page":"153830","DOI":"10.1016\/j.tox.2024.153830","volume":"505","author":"W Wu","year":"2024","unstructured":"Wu W, Sun J, Zhang J, Zhao H, Qiu S, Li C, Xu Y, et al. Phosphoproteomics reveals a novel mechanism underlying the proarrhythmic effects of nilotinib, vandetanib, and mobocertinib. Toxicology. 2024;505:153830.","journal-title":"Toxicology"},{"key":"1402_CR82","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.toxlet.2022.06.001","volume":"365","author":"X Cui","year":"2022","unstructured":"Cui X, Sun J, Li C, Qiu S, Shi C, Ma J, Xu Y. Downregulation of hERG channel expression by tyrosine kinase inhibitors nilotinib and vandetanib predominantly contributes to arrhythmogenesis. Toxicol Lett. 2022;365:11\u201323.","journal-title":"Toxicol Lett"},{"issue":"3","key":"1402_CR83","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1111\/bjh.19595","volume":"205","author":"A Gover-Proaktor","year":"2024","unstructured":"Gover-Proaktor A, Leshem-Lev D, Winograd-Katz S, Partouche S, Samara A, Shapira S, et al. Granot G. Dasatinib induces endothelial dysfunction leading to impaired recovery from ischaemia. Br J Haematol. 2024;205(3):1011\u20136.","journal-title":"Br J Haematol"},{"issue":"1","key":"1402_CR84","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","volume":"8","author":"S Shyam Sunder","year":"2023","unstructured":"Shyam Sunder S, Sharma UC, Pokharel S. Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management. Signal Transduct Target Ther. 2023;8(1):262.","journal-title":"Signal Transduct Target Ther"},{"key":"1402_CR85","doi-asserted-by":"crossref","unstructured":"Zakaria ZZ, Suleiman M, Benslimane FM, Al-Badr M, Sivaraman S, Korashy HM, Yalcin HC et al. Imatinib\u2013 and ponatinib\u2013mediated cardiotoxicity in zebrafish embryos and H9c2 cardiomyoblasts. Mol Med Rep.2024;30(4):187.","DOI":"10.3892\/mmr.2024.13311"},{"issue":"1","key":"1402_CR86","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s11899-020-00560-x","volume":"15","author":"D Gustafson","year":"2020","unstructured":"Gustafson D, Fish JE, Lipton JH, Aghel N. Mechanisms of Cardiovascular Toxicity of BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia. Curr Hematol Malig Rep. 2020;15(1):20\u201330.","journal-title":"Curr Hematol Malig Rep"},{"issue":"1","key":"1402_CR87","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.thromres.2014.11.009","volume":"135","author":"CP Loren","year":"2015","unstructured":"Loren CP, Aslan JE, Rigg RA, Nowak MS, Healy LD, Gruber A, et al. The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear. Thromb Res. 2015;135(1):155\u201360.","journal-title":"Thromb Res"},{"issue":"3","key":"1402_CR88","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jaccao.2022.06.004","volume":"4","author":"B Yu","year":"2022","unstructured":"Yu B, Osman AEG, Sladojevic N, Prabhu N, Tai HC, Chen D, Liao JK, et al. Involvement of Rho-Associated Coiled-Coil Containing Kinase (ROCK) in BCR-ABL1 Tyrosine Kinase Inhibitor Cardiovascular Toxicity. JACC CardioOncol. 2022;4(3):371\u201383.","journal-title":"JACC CardioOncol"},{"key":"1402_CR89","doi-asserted-by":"publisher","unstructured":"Alam MF, Hijri SI, Alshahrani S, Alqahtani SS, Jali AM, Ahmed RA, et al. Zingerone attenuates carfilzomib-induced cardiotoxicity in rats through oxidative stress and inflammatory cytokine network. Int J Mol Sci. 2022;23(24):15617. https:\/\/doi.org\/10.3390\/ijms232415617","DOI":"10.3390\/ijms232415617"},{"issue":"11","key":"1402_CR90","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1161\/CIRCULATIONAHA.125.073610","volume":"152","author":"A Stepanian","year":"2025","unstructured":"Stepanian A, Travers RJ, Tesfu A, Wolter NL, Man JJ, Lu Q, Jaffe IZ, Ponatinib, et al. But Not the New Abl-Kinase Inhibitor Asciminib, Activates Platelets, Leukocytes, and Endothelial Cell TNF Signaling to Induce Atherosclerotic Plaque Inflammation, Myocardial Infarction, and Stroke. Circulation. 2025;152(11):765\u201383.","journal-title":"Circulation"},{"key":"1402_CR91","first-page":"0509","volume":"7","author":"Y Li","year":"2024","unstructured":"Li Y, Liu X, Lin R, Peng X, Wang X, Meng F, et al. Liu N. Ibrutinib Promotes Atrial Fibrillation by Disrupting A-Kinase Anchoring Protein 1-Mediated Mitochondrial Quality Surveillance in Cardiomyocytes. Res (Wash D C). 2024;7:0509.","journal-title":"Res (Wash D C)"},{"issue":"22","key":"1402_CR92","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1161\/CIRCULATIONAHA.118.034621","volume":"138","author":"T Suetomi","year":"2018","unstructured":"Suetomi T, Willeford A, Brand CS, Cho Y, Ross RS, Miyamoto S, Brown JH. Inflammation and NLRP3 Inflammasome Activation Initiated in Response to Pressure Overload by Ca2+\/Calmodulin-Dependent Protein Kinase II \u03b4 Signaling in Cardiomyocytes Are Essential for Adverse Cardiac Remodeling. Circulation. 2018;138(22):2530\u201344.","journal-title":"Circulation"},{"issue":"5","key":"1402_CR93","doi-asserted-by":"publisher","first-page":"201","DOI":"10.31083\/j.fbl2905201","volume":"29","author":"H Qin","year":"2024","unstructured":"Qin H, Zheng B, Lin Z, Ji Y, Wang C, Zhu H, et al. Chen M. Ibrutinib Contributes to Atrial Arrhythmia through the Autophagic Degradation of Connexins by Inhibiting the PI3K-AKT-mTOR Signaling Pathway. Front Biosci (Landmark Ed). 2024;29(5):201.","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"25","key":"1402_CR94","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/blood-2014-10-604272","volume":"124","author":"JR McMullen","year":"2014","unstructured":"McMullen JR, Boey EJH, Ooi JYY, Seymour JF, Keating MJ, Tam CS. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood. 2014;124(25):3829\u201330.","journal-title":"Blood"},{"issue":"25","key":"1402_CR95","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1161\/CIRCULATIONAHA.120.049210","volume":"142","author":"L Xiao","year":"2020","unstructured":"Xiao L, Salem J-E, Clauss S, Hanley A, Bapat A, Hulsmans M, et al. Ibrutinib-mediated atrial fibrillation attributable to inhibition of C-terminal Src kinase. Circulation. 2020;142(25):2443\u201355.","journal-title":"Circulation"},{"issue":"3\u20134","key":"1402_CR96","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s10495-023-01911-8","volume":"29","author":"D Monogiou Belik","year":"2023","unstructured":"Monogiou Belik D, Bernasconi R, Xu L, Della Verde G, Lorenz V, Gr\u00fcterich V, Kuster GM, et al. The Flt3-inhibitor quizartinib augments apoptosis and promotes maladaptive remodeling after myocardial infarction in mice. Apoptosis. 2023;29(3\u20134):357\u201371.","journal-title":"Apoptosis"},{"issue":"7","key":"1402_CR97","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1182\/blood-2018-06-858415","volume":"133","author":"P Efentakis","year":"2019","unstructured":"Efentakis P, Kremastiotis G, Varela A, Nikolaou P-E, Papanagnou E-D, Davos CH, Terpos E, et al. Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin. Blood. 2019;133(7):710\u201323.","journal-title":"Blood"},{"issue":"9","key":"1402_CR98","doi-asserted-by":"publisher","first-page":"113228","DOI":"10.1016\/j.isci.2025.113228","volume":"28","author":"M Mendez-Lopez","year":"2025","unstructured":"Mendez-Lopez M, Besse A, Zuppinger C, Perez-Shibayama C, Gil-Cruz C, Florea BI, et al. Carfilzomib-specific proteasome \u03b25\/\u03b22 inhibition drives cardiotoxicity via remodeling of protein homeostasis and the renin-angiotensin-system. iScience. 2025;28(9):113228.","journal-title":"iScience"},{"issue":"24","key":"1402_CR99","doi-asserted-by":"publisher","first-page":"e022247","DOI":"10.1161\/JAHA.121.022247","volume":"10","author":"P Forghani","year":"2021","unstructured":"Forghani P, Rashid A, Sun F, Liu R, Li D, Lee MR, Xu C, et al. Carfilzomib Treatment Causes Molecular and Functional Alterations of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes. J Am Heart Assoc. 2021;10(24):e022247.","journal-title":"J Am Heart Assoc"},{"key":"1402_CR100","doi-asserted-by":"publisher","unstructured":"Wang S, Wang J, Li X, Dai Z, Li T, Wang Y, et al. Carfilzomib triggers cardiotoxicity by suppressing SENP1-mediated deSUMOylation of DDX17. Acta Biochim Biophys Sin (Shanghai). Published online October 9, 2025. https:\/\/doi.org\/10.3724\/abbs.2025121","DOI":"10.3724\/abbs.2025121"},{"issue":"1","key":"1402_CR101","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000492840","volume":"49","author":"P Lugenbiel","year":"2018","unstructured":"Lugenbiel P, Govorov K, Rahm A-K, Wieder T, Gramlich D, Syren P, Thomas D, et al. Inhibition of Histone Deacetylases Induces K+ Channel Remodeling and Action Potential Prolongation in HL-1 Atrial Cardiomyocytes. Cell Physiol Biochem. 2018;49(1):65\u201377.","journal-title":"Cell Physiol Biochem"},{"issue":"5","key":"1402_CR102","doi-asserted-by":"publisher","first-page":"H1139","DOI":"10.1152\/ajpheart.00156.2016","volume":"311","author":"Q Xu","year":"2016","unstructured":"Xu Q, Patel D, Zhang X, Veenstra RD. Changes in cardiac Nav1.5 expression, function, and acetylation by pan-histone deacetylase inhibitors. Am J Physiol Heart Circ Physiol. 2016;311(5):H1139\u201349.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"1402_CR103","doi-asserted-by":"publisher","unstructured":"AlAsmari AF, Alghamdi A, Ali N, Almeaikl MA, Hakami HM, Alyousef MK, et al. Venetoclax induces cardiotoxicity through modulation of oxidative-stress-mediated cardiac inflammation and apoptosis via NF-\u03baB and BCL-2 pathway. Int J Mol Sci. 2022; 23(11):6260. https:\/\/doi.org\/10.3390\/ijms23116260","DOI":"10.3390\/ijms23116260"},{"issue":"26","key":"1402_CR104","doi-asserted-by":"publisher","first-page":"6226","DOI":"10.1182\/blood-2012-01-400515","volume":"119","author":"M Klinger","year":"2012","unstructured":"Klinger M, Brandl C, Zugmaier G, Hijazi Y, Bargou RC, Topp MS, Kufer P, et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19\/CD3-bispecific BiTE antibody blinatumomab. Blood. 2012;119(26):6226\u201333.","journal-title":"Blood"},{"issue":"6","key":"1402_CR105","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s00395-020-00827-7","volume":"115","author":"FE Mason","year":"2020","unstructured":"Mason FE, Pronto JRD, Alhussini K, Maack C, Voigt N. Cellular and mitochondrial mechanisms of atrial fibrillation. Basic Res Cardiol. 2020;115(6):72.","journal-title":"Basic Res Cardiol"},{"issue":"2","key":"1402_CR106","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1161\/CIRCRESAHA.124.323800","volume":"135","author":"A Hinton","year":"2024","unstructured":"Hinton A, Claypool SM, Neikirk K, Senoo N, Wanjalla CN, Kirabo A, Williams CR. Mitochondrial Structure and Function in Human Heart Failure. Circ Res. 2024;135(2):372\u201396.","journal-title":"Circ Res"},{"key":"1402_CR107","doi-asserted-by":"publisher","first-page":"645122","DOI":"10.3389\/fcvm.2021.645122","volume":"8","author":"M Tantawy","year":"2021","unstructured":"Tantawy M, Chekka LM, Huang Y, Garrett TJ, Singh S, Shah CP, et al. Gong Y. Lactate Dehydrogenase B and Pyruvate Oxidation Pathway Associated With Carfilzomib-Related Cardiotoxicity in Multiple Myeloma Patients: Result of a Multi-Omics Integrative Analysis. Front Cardiovasc Med. 2021;8:645122.","journal-title":"Front Cardiovasc Med"},{"issue":"5","key":"1402_CR108","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1093\/cvr\/cvac134","volume":"119","author":"E Murphy","year":"2023","unstructured":"Murphy E, Liu JC. Mitochondrial calcium and reactive oxygen species in cardiovascular disease. Cardiovasc Res. 2023;119(5):1105\u201316.","journal-title":"Cardiovasc Res"},{"key":"1402_CR109","doi-asserted-by":"publisher","first-page":"101432","DOI":"10.1016\/j.redox.2020.101432","volume":"30","author":"X Yang","year":"2020","unstructured":"Yang X, An N, Zhong C, Guan M, Jiang Y, Li X, Xing Y, et al. Enhanced cardiomyocyte reactive oxygen species signaling promotes ibrutinib-induced atrial fibrillation. Redox Biol. 2020;30:101432.","journal-title":"Redox Biol"},{"issue":"1","key":"1402_CR110","doi-asserted-by":"publisher","first-page":"5295","DOI":"10.1038\/s41598-018-23630-w","volume":"8","author":"C Schneider","year":"2018","unstructured":"Schneider C, Wallner M, Kolesnik E, Herbst V, M\u00e4chler H, Pichler M, et al. The anti-cancer multikinase inhibitor sorafenib impairs cardiac contractility by reducing phospholamban phosphorylation and sarcoplasmic calcium transients. Sci Rep. 2018;8(1):5295.","journal-title":"Sci Rep"},{"issue":"8","key":"1402_CR111","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1002\/sctm.18-0279","volume":"8","author":"P Nair","year":"2019","unstructured":"Nair P, Prado M, Perea-Gil I, Karakikes I. Concise Review: Precision Matchmaking: Induced Pluripotent Stem Cells Meet Cardio-Oncology. Stem Cells Transl Med. 2019;8(8):758\u201367.","journal-title":"Stem Cells Transl Med"},{"issue":"20","key":"1402_CR112","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1161\/CIRCULATIONAHA.118.035202","volume":"138","author":"C Yao","year":"2018","unstructured":"Yao C, Veleva T, Scott L, Cao S, Li L, Chen G, et al. Li N. Enhanced Cardiomyocyte NLRP3 Inflammasome Signaling Promotes Atrial Fibrillation. Circulation. 2018;138(20):2227\u201342.","journal-title":"Circulation"},{"issue":"4","key":"1402_CR113","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1172\/JCI128322","volume":"130","author":"L Mao","year":"2020","unstructured":"Mao L, Kitani A, Hiejima E, Montgomery-Recht K, Zhou W, Fuss I, Strober W, et al. Bruton tyrosine kinase deficiency augments NLRP3 inflammasome activation and causes IL-1\u03b2-mediated colitis. J Clin Invest. 2020;130(4):1793\u2013807.","journal-title":"J Clin Invest"},{"key":"1402_CR114","doi-asserted-by":"publisher","unstructured":"Bittner ZA, Liu X, Mateo Tortola M, Tapia-Abell\u00e1n A, Shankar S, Andreeva L, et al. BTK operates a phospho-tyrosine switch to regulate NLRP3 inflammasome activity. J Exp Med. 2021;218(11):e20201656. https:\/\/doi.org\/10.1084\/jem.20201656","DOI":"10.1084\/jem.20201656"},{"key":"1402_CR115","doi-asserted-by":"publisher","first-page":"1190099","DOI":"10.3389\/fcvm.2023.1190099","volume":"10","author":"D Tarnowski","year":"2023","unstructured":"Tarnowski D, Feder AL, Trum M, Kreitmeier KG, Stengel L, Maier LS, Sag CM. Ibrutinib impairs IGF-1-dependent activation of intracellular Ca handling in isolated mouse ventricular myocytes. Front Cardiovasc Med. 2023;10:1190099.","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"1402_CR116","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/toxsci\/kfw104","volume":"153","author":"S Spence","year":"2016","unstructured":"Spence S, Deurinck M, Ju H, Traebert M, McLean L, Marlowe J, et al. Friedrichs GS. Histone Deacetylase Inhibitors Prolong Cardiac Repolarization through Transcriptional Mechanisms. Toxicol Sci. 2016;153(1):39\u201354.","journal-title":"Toxicol Sci"},{"key":"1402_CR117","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3389\/fphar.2013.00044","volume":"4","author":"Q Xu","year":"2013","unstructured":"Xu Q, Lin X, Andrews L, Patel D, Lampe PD, Veenstra RD. Histone deacetylase inhibition reduces cardiac connexin43 expression and gap junction communication. Front Pharmacol. 2013;4:44.","journal-title":"Front Pharmacol"},{"key":"1402_CR118","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3389\/fphar.2015.00168","volume":"6","author":"N Fatima","year":"2015","unstructured":"Fatima N, Cohen DC, Sukumar G, Sissung TM, Schooley JF, Haigney MC, Flagg TP, et al. Histone deacetylase inhibitors modulate KATP subunit transcription in HL-1 cardiomyocytes through effects on cholesterol homeostasis. Front Pharmacol. 2015;6:168.","journal-title":"Front Pharmacol"},{"key":"1402_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/j.yjmcc.2019.05.008","author":"P Zhabyeyev","year":"2019","unstructured":"Zhabyeyev P, McLean B, Chen X, Vanhaesebroeck B, Oudit GY. Inhibition of PI3Kinase-\u03b1 is pro-arrhythmic and associated with enhanced late Na+ current, contractility, and Ca2\u2009+\u2009release in murine hearts. J Mol Cell Cardiol. 2019;132:98\u2013109. https:\/\/doi.org\/10.1016\/j.yjmcc.2019.05.008","journal-title":"J Mol Cell Cardiol"},{"issue":"10","key":"1402_CR120","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.7150\/ijbs.5141","volume":"8","author":"M Okada","year":"2012","unstructured":"Okada M. Regulation of the SRC family kinases by Csk. Int J Biol Sci. 2012;8(10):1385\u201397.","journal-title":"Int J Biol Sci"},{"issue":"5","key":"1402_CR121","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1093\/cvr\/cvz006","volume":"115","author":"AP Singh","year":"2019","unstructured":"Singh AP, Glennon MS, Umbarkar P, Gupte M, Galindo CL, Zhang Q, Lal H, et al. Ponatinib-induced cardiotoxicity: delineating the signalling mechanisms and potential rescue strategies. Cardiovasc Res. 2019;115(5):966\u201377.","journal-title":"Cardiovasc Res"},{"issue":"10","key":"1402_CR122","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1161\/ATVBAHA.124.319864","volume":"44","author":"RJ Travers","year":"2024","unstructured":"Travers RJ, Stepanian A, Jaffe IZ. Endothelium as a Source of Cardiovascular Toxicity From Antitumor Kinase Inhibitors. Arterioscler Thromb Vasc Biol. 2024;44(10):2143\u201353.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"1402_CR123","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s13577-024-01052-3","volume":"37","author":"J Yao","year":"2024","unstructured":"Yao J, Chen Y, Huang Y, Sun X, Shi X. The role of cardiac microenvironment in cardiovascular diseases: implications for therapy. Hum Cell. 2024;37(3):607\u201324.","journal-title":"Hum Cell"},{"issue":"2","key":"1402_CR124","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/nri3800","volume":"15","author":"S Epelman","year":"2015","unstructured":"Epelman S, Liu PP, Mann DL. Role of innate and adaptive immune mechanisms in cardiac injury and repair. Nat Rev Immunol. 2015;15(2):117\u201329.","journal-title":"Nat Rev Immunol"},{"key":"1402_CR125","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25021082","author":"H Zhang","year":"2024","unstructured":"Zhang H, Dhalla NS. The role of pro-inflammatory cytokines in the pathogenesis of cardiovascular disease. Int J Mol Sci. 2024;25(2):1082. https:\/\/doi.org\/10.3390\/ijms25021082","journal-title":"Int J Mol Sci"},{"issue":"5","key":"1402_CR126","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41569-019-0315-x","volume":"17","author":"L Adamo","year":"2020","unstructured":"Adamo L, Rocha-Resende C, Prabhu SD, Mann DL. Reappraising the role of inflammation in heart failure. Nat Rev Cardiol. 2020;17(5):269\u201385.","journal-title":"Nat Rev Cardiol"},{"issue":"5","key":"1402_CR127","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nrcardio.2014.28","volume":"11","author":"NG Frangogiannis","year":"2014","unstructured":"Frangogiannis NG. The inflammatory response in myocardial injury, repair, and remodelling. Nat Rev Cardiol. 2014;11(5):255\u201365.","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"1402_CR128","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s12933-024-02210-5","volume":"23","author":"W Guo","year":"2024","unstructured":"Guo W, Zhao L, Huang W, Chen J, Zhong T, Yan S, Yan H, et al. Sodium-glucose cotransporter 2 inhibitors, inflammation, and heart failure: a two-sample Mendelian randomization study. Cardiovasc Diabetol. 2024;23(1):118.","journal-title":"Cardiovasc Diabetol"},{"issue":"11","key":"1402_CR129","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1002\/ejhf.942","volume":"19","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Bauersachs J, Langer HF. Immune mechanisms in heart failure. Eur J Heart Fail. 2017;19(11):1379\u201389.","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"1402_CR130","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1002\/eji.201141550","volume":"41","author":"CA Dinarello","year":"2011","unstructured":"Dinarello CA. A clinical perspective of IL-1\u03b2 as the gatekeeper of inflammation. Eur J Immunol. 2011;41(5):1203\u201317.","journal-title":"Eur J Immunol"},{"issue":"5","key":"1402_CR131","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1161\/CIRCRESAHA.124.324164","volume":"134","author":"FG Liang","year":"2024","unstructured":"Liang FG, Moslehi J, Kitsis RN. Ponatinib-Induced Cardiomyocyte Toxicity: Dark Side of the Integrated Stress Response. Circ Res. 2024;134(5):502\u20134.","journal-title":"Circ Res"},{"issue":"22","key":"1402_CR132","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1093\/eurheartj\/ehy365","volume":"40","author":"P Ferdinandy","year":"2019","unstructured":"Ferdinandy P, Baczk\u00f3 I, Bencsik P, Giricz Z, G\u00f6rbe A, Pacher P, Schulz R, et al. Definition of hidden drug cardiotoxicity: paradigm change in cardiac safety testing and its clinical implications. Eur Heart J. 2019;40(22):1771\u20137.","journal-title":"Eur Heart J"},{"issue":"41","key":"1402_CR133","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR van der Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, Asteggiano R, Aznar MC, van der Bergler-Klein J, Pal HJH, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229\u2013361.","journal-title":"Eur Heart J"},{"issue":"16","key":"1402_CR134","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/j.jacc.2022.08.743","volume":"80","author":"LA Baldassarre","year":"2022","unstructured":"Baldassarre LA, Ganatra S, Lopez-Mattei J, Yang EH, Zaha VG, Wong TC, et al. Advances in multimodality imaging in cardio-oncology: JACC state-of-the-art review. J Am Coll Cardiol. 2022;80(16):1560\u201378.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"1402_CR135","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s11912-022-01242-y","volume":"24","author":"TH Marwick","year":"2022","unstructured":"Marwick TH. Global Longitudinal Strain Monitoring to Guide Cardioprotective Medications During Anthracycline Treatment. Curr Oncol Rep. 2022;24(6):687\u201394.","journal-title":"Curr Oncol Rep"},{"key":"1402_CR136","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030986","author":"G S\u0142awi\u0144ski","year":"2023","unstructured":"S\u0142awi\u0144ski G, Hawryszko M, Li\u017cewska-Springer A, Nabia\u0142ek-Trojanowska I, Lewicka E. Global longitudinal strain in cardio-oncology: a review. Cancers (Basel). 2023;15(3):986. https:\/\/doi.org\/10.3390\/cancers15030986","journal-title":"Cancers (Basel)"},{"key":"1402_CR137","doi-asserted-by":"publisher","DOI":"10.1007\/s00395-024-01080-y","author":"AE Vi\u00f1as-Mendieta","year":"2024","unstructured":"Vi\u00f1as-Mendieta AE, Gallardo-Grajeda A, L\u00f3pez-Fern\u00e1ndez T. Cardio-oncology: chances and challenges. Basic Res Cardiol. 2025;120(1):3\u20139 https:\/\/doi.org\/10.1007\/s00395-024-01080-y","journal-title":"Basic Res Cardiol"},{"issue":"8","key":"1402_CR138","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1093\/ehjci\/jeu313","volume":"16","author":"CA Pickett","year":"2015","unstructured":"Pickett CA, Cheezum MK, Kassop D, Villines TC, Hulten EA. Accuracy of cardiac CT, radionucleotide and invasive ventriculography, two- and three-dimensional echocardiography, and SPECT for left and right ventricular ejection fraction compared with cardiac MRI: a meta-analysis. Eur Heart J Cardiovasc Imaging. 2015;16(8):848\u201352.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"45","key":"1402_CR139","doi-asserted-by":"publisher","first-page":"4738","DOI":"10.1093\/eurheartj\/ehad510","volume":"44","author":"DC Benz","year":"2023","unstructured":"Benz DC, Gr\u00e4ni C, Antiochos P, Heydari B, Gissler MC, Ge Y, Kwong RY, et al. Cardiac magnetic resonance biomarkers as surrogate endpoints in cardiovascular trials for myocardial diseases. Eur Heart J. 2023;44(45):4738\u201347.","journal-title":"Eur Heart J"},{"issue":"7","key":"1402_CR140","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1016\/j.jcmg.2021.11.017","volume":"15","author":"C Eichhorn","year":"2022","unstructured":"Eichhorn C, Greulich S, Bucciarelli-Ducci C, Sznitman R, Kwong RY, Gr\u00e4ni C. Multiparametric Cardiovascular Magnetic Resonance Approach in Diagnosing, Monitoring, and Prognostication of Myocarditis. JACC Cardiovasc Imaging. 2022;15(7):1325\u201338.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"8","key":"1402_CR141","doi-asserted-by":"publisher","first-page":"e29720","DOI":"10.1002\/pbc.29720","volume":"69","author":"EC de Baat","year":"2022","unstructured":"de Baat EC, Feijen EAM, van Niekerk JB, Mavinkurve-Groothuis AMC, Kapusta L, Loonen J, van, der Pal HJH, et al. Electrocardiographic abnormalities in childhood cancer survivors treated with cardiotoxic therapy: a systematic review. Pediatr Blood Cancer. 2022;69(8):e29720.","journal-title":"Pediatr Blood Cancer"},{"issue":"11","key":"1402_CR142","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1002\/ejhf.1920","volume":"22","author":"AR Lyon","year":"2020","unstructured":"Lyon AR, Dent S, Stanway S, Earl H, Brezden-Masley C, Cohen-Solal A, Lenihan D, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. 2020;22(11):1945\u201360.","journal-title":"Eur J Heart Fail"},{"issue":"14","key":"1402_CR143","doi-asserted-by":"publisher","first-page":"3601","DOI":"10.1158\/1078-0432.CCR-16-2869","volume":"23","author":"V Narayan","year":"2017","unstructured":"Narayan V, Keefe S, Haas N, Wang L, Puzanov I, Putt M, et al. Ky B. Prospective Evaluation of Sunitinib-Induced Cardiotoxicity in Patients with Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2017;23(14):3601\u20139.","journal-title":"Clin Cancer Res"},{"issue":"21","key":"1402_CR144","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1161\/CIRCULATIONAHA.123.064274","volume":"148","author":"PA Henriksen","year":"2023","unstructured":"Henriksen PA, Hall P, MacPherson IR, Joshi SS, Singh T, Maclean M, Lang NN, et al. Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial. Circulation. 2023;148(21):1680\u201390.","journal-title":"Circulation"},{"issue":"3","key":"1402_CR145","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1093\/cvr\/cvac087","volume":"119","author":"C Tonry","year":"2023","unstructured":"Tonry C, Russell-Hallinan A, McCune C, Collier P, Harbinson M, Dixon L, Watson CJ. Circulating biomarkers for management of cancer therapeutics-related cardiac dysfunction. Cardiovasc Res. 2023;119(3):710\u201328.","journal-title":"Cardiovasc Res"},{"issue":"8","key":"1402_CR146","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.jacc.2013.10.061","volume":"63","author":"B Ky","year":"2014","unstructured":"Ky B, Putt M, Sawaya H, French B, Januzzi JL, Sebag IA, Scherrer-Crosbie M, et al. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol. 2014;63(8):809\u201316.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"1402_CR147","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1373\/clinchem.2015.241232","volume":"61","author":"M Putt","year":"2015","unstructured":"Putt M, Hahn VS, Januzzi JL, Sawaya H, Sebag IA, Plana JC, et al. Ky B. Longitudinal Changes in Multiple Biomarkers Are Associated with Cardiotoxicity in Breast Cancer Patients Treated with Doxorubicin, Taxanes, and Trastuzumab. Clin Chem. 2015;61(9):1164\u201372.","journal-title":"Clin Chem"},{"key":"1402_CR148","first-page":"2","volume":"6","author":"JM Canada","year":"2020","unstructured":"Canada JM, Thomas GK, Trankle CR, Carbone S, Billingsley H, Van Tassell BW, et al. Abbate A. Increased C-reactive protein is associated with the severity of thoracic radiotherapy-induced cardiomyopathy. Cardiooncology. 2020;6:2.","journal-title":"Cardiooncology"},{"issue":"22","key":"1402_CR149","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1093\/eurheartj\/ehad117","volume":"44","author":"SS Mahmood","year":"2023","unstructured":"Mahmood SS, Riedell PA, Feldman S, George G, Sansoterra SA, Althaus T, Steingart RM, et al. Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients. Eur Heart J. 2023;44(22):2029\u201342.","journal-title":"Eur Heart J"},{"issue":"4","key":"1402_CR150","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1093\/cvr\/cvq148","volume":"87","author":"T Horie","year":"2010","unstructured":"Horie T, Ono K, Nishi H, Nagao K, Kinoshita M, Watanabe S, Kimura T, et al. Acute doxorubicin cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin-ErbB pathway. Cardiovasc Res. 2010;87(4):656\u201364.","journal-title":"Cardiovasc Res"},{"issue":"1","key":"1402_CR151","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jaccao.2020.12.003","volume":"3","author":"ES Lau","year":"2021","unstructured":"Lau ES, Paniagua SM, Liu E, Jovani M, Li SX, Takvorian K, et al. Cardiovascular risk factors are associated with future cancer. JACC CardioOnc. 2021;3(1):48\u201358.","journal-title":"JACC CardioOnc"},{"issue":"3","key":"1402_CR152","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1002\/ehf2.13897","volume":"9","author":"D Di Lisi","year":"2022","unstructured":"Di Lisi D, Madaudo C, Alagna G, Santoro M, Rossetto L, Siragusa S, Novo G. The new HFA\/ICOS risk assessment tool to identify patients with chronic myeloid leukaemia at high risk of cardiotoxicity. ESC Heart Fail. 2022;9(3):1914\u20139.","journal-title":"ESC Heart Fail"},{"issue":"3","key":"1402_CR153","doi-asserted-by":"publisher","first-page":"240","DOI":"10.21147\/j.issn.1000-9604.2024.03.02","volume":"36","author":"Z Song","year":"2024","unstructured":"Song Z, Jiang D, Yu L, Chen Y, Zhou D, Li Y, et al. Cross-Straits Medicine Exchange Association Smea HPPCO. Evidence-based expert consensus on clinical management of safety of Bruton\u2019s tyrosine kinase inhibitors (2024). Chin J Cancer Res. 2024;36(3):240\u201356.","journal-title":"Chin J Cancer Res"},{"issue":"1","key":"1402_CR154","first-page":"1","volume":"5","author":"G Georgiopoulos","year":"2023","unstructured":"Georgiopoulos G, Makris N, Laina A, Theodorakakou F, Briasoulis A, Trougakos IP, Stamatelopoulos K, et al. Cardiovascular Toxicity of Proteasome Inhibitors: Underlying Mechanisms and Management Strategies. JACC: CardioOncology. 2023;5(1):1\u201321.","journal-title":"JACC: CardioOncology"},{"issue":"18","key":"1402_CR155","doi-asserted-by":"publisher","first-page":"5516","DOI":"10.1182\/bloodadvances.2022007938","volume":"6","author":"FT Awan","year":"2022","unstructured":"Awan FT, Addison D, Alfraih F, Baratta SJ, Campos RN, Cugliari MS, Ysebaert L, et al. International consensus statement on the management of cardiovascular risk of Bruton\u2019s tyrosine kinase inhibitors in CLL. Blood Adv. 2022;6(18):5516\u201325.","journal-title":"Blood Adv"},{"issue":"1","key":"1402_CR156","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1038\/s41467-024-45733-x","volume":"15","author":"R Yagi","year":"2024","unstructured":"Yagi R, Goto S, Himeno Y, Katsumata Y, Hashimoto M, MacRae CA, Deo RC. Artificial intelligence-enabled prediction of chemotherapy-induced cardiotoxicity from baseline electrocardiograms. Nat Commun. 2024;15(1):2536.","journal-title":"Nat Commun"},{"issue":"5","key":"1402_CR157","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1093\/eurjpc\/zwad348","volume":"31","author":"JEJ Jacobs","year":"2024","unstructured":"Jacobs JEJ, Greason G, Mangold KE, Wildiers H, Willems R, Janssens S, Herrmann J, et al. Artificial intelligence electrocardiogram as a novel screening tool to detect a newly abnormal left ventricular ejection fraction after anthracycline-based cancer therapy. Eur J Prev Cardiol. 2024;31(5):560\u20136.","journal-title":"Eur J Prev Cardiol"},{"key":"1402_CR158","doi-asserted-by":"crossref","unstructured":"Madan N, Lucas J, Akhter N, Collier P, Cheng F, Guha A et al. Brown S-A. Artificial intelligence and imaging: Opportunities in cardio-oncology. Am Heart J Plus. 2022;15:100126.","DOI":"10.1016\/j.ahjo.2022.100126"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-026-01402-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-026-01402-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-026-01402-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T20:01:59Z","timestamp":1792526519000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-026-01402-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":158,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["1402"],"URL":"https:\/\/doi.org\/10.1007\/s11864-026-01402-3","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"assertion":[{"value":"26 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In this article, the affiliation for Nengming Lin was incorrectly given as 'Department of Clinical Pharmacy, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, School of Medicine, Affiliated Hangzhou First People\u2019s Hospital, Westlake University, 261 Huansha Road, Hangzhou, Zhejiang 310006, China' but should have been 'School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, China'.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"35"}}